source
- Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressureA million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion D…Endpoints · 2mo ago↗ source
- Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharmaIntercept Pharmaceuticals' attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended. The drug developer's INT-787 showed "no clear evidence of…Endpoints · 2mo ago↗ source
- Pfizer's Albert Bourla says he has no mega-merger plansThe most candid man in pharma strikes again. When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near or medium term, CEO Albert Bourla said it wo…